To REMS, or not to REMS. That apparently was the question for Cytokinetics, which has seen any potential approval for its ...

Both years were unusually high, as the highest amount of bankruptcy filings since the high-water mark of 14 in 2010 was only ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

Shares of Bristol Myers Squibb Co. BMY shed 1.18% to $49.61 Thursday, on what proved to be an all-around great trading ...

We recently published a list of 10 Jim Cramer Stocks to Watch Amid Trump Tariff Wars. In this article, we are going to take a ...

The IMPACT trial reinforces the need to check for antiphospholipid syndrome in women after they experience stillbirth and is ...

This was the stock's third consecutive day of gains.

The four anti-CD20 drugs used in the U.S. to treat relapsing MS -- ocrelizumab, ofatumumab, and ublituximab (Briumvi; ...

Everyone remembers Chris Martin and Gwyneth Paltrow making "conscious uncoupling" a divorce trend in 2014. Now, the ...

Business & Finance Media Group in partnership with Ibec has launched the Top 100 Companies Leading In Wellbeing Index 2025.

Many companies have foreshadowed deals to come during earnings calls in recent days. The return of M&A would be a welcome ...

One big pharma name stands out as an exceptional opportunity: Bristol Myers Squibb ( BMY 1.61%). The stock has been pummeled ...